Kyverna Therapeutics filings document a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. Its Form 8-K disclosures frequently cover Regulation FD updates for miv-cel clinical data, business and financial results, and material corporate events involving leadership, board composition, and commercial organization changes.
The company's proxy and governance filings describe director elections, board committees, executive compensation, stockholder voting matters, and equity incentive arrangements, including inducement awards. SEC records also identify Kyverna's Nasdaq-listed common stock and provide formal disclosure around its CAR T development strategy, clinical programs in neuroimmunology, capital planning, risk factors, and public-company governance.
Kyverna Therapeutics, Inc. appointed Gregory (Greg) Martini as Chief Financial Officer, effective May 18, 2026, succeeding Marc Grasso, M.D., who will remain as a strategic advisor through August 1, 2026 to support a smooth transition. Martini becomes Kyverna’s principal financial and accounting officer.
Under his offer letter, Martini receives a $525,000 base salary, an annual bonus opportunity equal to 40% of salary (pro‑rated for 2026), and a $300,000 sign‑on bonus, split into two $150,000 payments tied to his start date and first anniversary. He will also be granted a stock option to purchase 325,000 shares of common stock under Kyverna’s 2024 Inducement Equity Incentive Plan, vesting over four years, along with severance and change‑in‑control protections.
Kyverna states that Grasso’s transition is not due to any disagreement over operations or financial reporting. The accompanying press release highlights Martini’s prior CFO role at Ironwood Pharmaceuticals and frames his hire as supporting Kyverna’s evolution into a commercial‑stage company as it advances its CAR T‑cell therapy candidate miv‑cel toward potential approval in autoimmune diseases.
Kyverna Therapeutics initiated a rolling biologics license application (BLA) submission for its CAR T-cell therapy miv-cel in stiff person syndrome (SPS) after a positive pre-BLA meeting with the FDA confirming that the single-arm KYSA-8 trial can support the filing and potential priority review under its RMAT designation. The company reported robust, durable SPS data with all patients off immunotherapies through last follow-up, and encouraging results across generalized myasthenia gravis and progressive multiple sclerosis programs.
For the quarter ended March 31, 2026, Kyverna reported a net loss of $39.7 million, or $0.66 per share, on operating expenses of $41.4 million. Cash, cash equivalents and marketable securities were $236.4 million, and management continues to expect a cash runway into 2028 while advancing launch readiness for a potential SPS commercial rollout.
Kyverna Therapeutics granted Chief Commercial Officer Nadia Dac a stock option to acquire 300,000 shares of common stock at an exercise price of $9.00 per share, expiring on May 4, 2036. This is a compensation award, not an open-market share purchase.
One quarter of the option vests on May 4, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on her continuous service with the company.
Kyverna Therapeutics, Inc. filed a Form 3 identifying Nadia Dac as a reporting person in her role as Chief Commercial Officer. This Form 3 serves as an initial statement of insider status for SEC reporting. The provided data show no reported share purchases, sales, or other transactions in this filing.
Kyverna Therapeutics, Inc. appointed veteran commercial leader Nadia Dac as Chief Commercial Officer, effective May 4, 2026. She will lead commercial strategy and execution for miv-cel (mivocabtagene autoleucel, KYV-101), a CD19-targeting CAR T-cell therapy being developed for stiff person syndrome and other B‑cell-driven autoimmune diseases.
In connection with her appointment, Kyverna will grant Ms. Dac an option to purchase 300,000 shares of common stock under its Amended and Restated 2024 Inducement Equity Incentive Plan, as an inducement award under Nasdaq Listing Rule 5635(c)(4). The option will have an exercise price equal to the closing price on May 4, 2026 and will vest over four years, with 25% vesting on the one-year anniversary of her appointment and the remainder vesting in equal monthly installments thereafter, subject to continued service.
Kyverna Therapeutics reported strong clinical data for its autoimmune CAR T therapy miv-cel (KYV‑101) in two registrational programs, stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). The results were highlighted in a presentation tied to a conference call and recent press releases.
In the SPS Phase 2 KYSA‑8 registrational trial (n=26), patients had a 46% median improvement in the timed 25‑foot walk at week 16, with 81% achieving at least a 20% improvement and all remaining off SPS immunomodulatory or immunosuppressive therapies through last follow‑up. Secondary measures of disability, stiffness, and hypersensitivity all improved significantly, and no high‑grade cytokine release syndrome (CRS) or ICANS occurred.
In the gMG Phase 2 KYSA‑6 trial (n=7), a single miv‑cel dose produced rapid, durable reductions in MG‑ADL and QMG scores out to 52 weeks, with 100% of patients achieving clinically meaningful responses and 57% reaching minimal symptom expression. All patients were free of immunotherapies through 24 weeks, with a favorable safety profile and evidence of deep B‑cell depletion, autoantibody reduction, and preserved humoral immunity. The company is preparing a BLA for SPS and advancing a global Phase 3 trial in gMG.
Kyverna Therapeutics reported positive primary analysis results from its registrational Phase 2 KYSA-8 trial of miv-cel (KYV-101) in stiff person syndrome (SPS). A single dose of 1×108 CAR T cells in 26 patients led to rapid, statistically significant and clinically meaningful improvements in walking speed, disability, stiffness, hypersensitivity, and mobility at 16 weeks, with a median 46% improvement in the Timed 25-Foot Walk and 81% of patients achieving at least a 20% improvement.
All patients discontinued chronic immunotherapies by Week 16, and two-thirds of those who needed walking aids at baseline no longer required them. Miv-cel showed a favorable safety profile with no high-grade CRS or ICANS and manageable Grade 3/4 neutropenia, supporting Kyverna’s plans to prepare a BLA submission for SPS.
Kyverna Therapeutics reported longer-term Phase 2 data from its KYSA-6 registrational trial of miv-cel (KYV-101) in generalized myasthenia gravis. Seven patients with moderate-to-severe disease received a single dose, showing deep, durable responses across key clinical scores and reduced treatment burden.
At 24 weeks, all patients had rapid, clinically meaningful improvements in MG-ADL and QMG scores, with many maintaining benefits out to 52 weeks. All were free of nonsteroidal immunosuppressants, high-dose steroids, and FcRn or complement inhibitors at 24 weeks, and safety was favorable with no high-grade CRS or ICANS.
KYTX filed a Form 144 reporting a proposed sale of 10,000 common shares following an exercise of stock options, dated 04/17/2026. The filing lists an aggregate figure of $95,300.00 and identifies Morgan Stanley Smith Barney LLC as the broker on NASDAQ. The filing also discloses recent 10b5-1 sales by Karen Walker of 2,459 shares on 04/14/2026 for $22,889.11.